Literature DB >> 9543293

Magnetic resonance imaging of the thorax in the evaluation of asbestosis.

S I Bekkelund1, U Aasebø, C Pierre-Jerome, J Holmboe.   

Abstract

The purpose of the study was to evaluate the accuracy of magnetic resonance imaging (MRI) in detecting subclinical morphological changes caused by asbestos exposure. Conventional chest radiographs according to the International Labour Organisation (ILO) categories 0-11 and spirometric data were compared with MRI in 17 men with mean (+/-2SD) asbestos exposure time of 24.6+/-13.0 yrs. Mean age was 62.0+/-9.4 yrs. The inclusion criterion was an ILO score of 2 or more. Electrocardiographic registrations and antirespiratory movement artefact techniques were used in all MRI examinations to avoid movement artefacts. Mean ILO grading was found to be 7.7+/-3.8 on chest radiography and 9.8+/-2.0 with MRI (p=0.01). Five patients had a higher ILO stage as evaluated by MRI, but in nine patients the staging remained unchanged. MRI revealed mediastinal adenopathy in four patients. Forced expiratory volume in one second (expressed as a percentage of the predicted value) was negatively correlated with ILO score as assessed by MRI (r=-0.4, p=0.032). Magnetic resonance imaging seems to be more sensitive than conventional radiographs in detecting subclinical fibrosis as well as the extent of pleural asbestosis.

Entities:  

Mesh:

Year:  1998        PMID: 9543293     DOI: 10.1183/09031936.98.11010194

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  2 in total

Review 1.  Applications of Magnetic Resonance Imaging of the Thorax in Pleural Diseases: A State-of-the-Art Review.

Authors:  Fernanda Miraldi Clemente Pessôa; Alessandro Severo Alves de Melo; Arthur Soares Souza; Luciana Soares de Souza; Bruno Hochhegger; Gláucia Zanetti; Edson Marchiori
Journal:  Lung       Date:  2016-06-14       Impact factor: 2.584

2.  3T MRI in evaluation of asbestos-related thoracic diseases - preliminary results.

Authors:  Janez Podobnik; Igor Kocijancic; Viljem Kovac; Igor Sersa
Journal:  Radiol Oncol       Date:  2010-05-24       Impact factor: 2.991

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.